Oral salmon calcitonin

DRUG4 trials

Sponsors

Université Catholique de Louvain, Novartis, Nordic Bioscience A/S

Conditions

OsteoarthritisPostmenopausal Osteoporosis

Phase 1

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

CompletedNCT00411125

NovartisPostmenopausal Osteoporosis

Start: 2006-08-31End: 2006-11-30Target: 86Updated: 2006-12-13

SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

CompletedNCT00486369

Nordic Bioscience A/SOsteoarthritis

Start: 2007-01-31Updated: 2007-06-14

Phase 2

Effects of Oral Salmon Calcitonin in Human Osteoarthritis

TerminatedNCT00376311

Université Catholique de LouvainOsteoarthritis

Start: 2002-09-30End: 2004-05-31Target: 54Updated: 2006-09-14

Phase 3

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

TerminatedNCT00704847

Nordic Bioscience A/SOsteoarthritis

Start: 2008-06-30End: 2011-06-30Updated: 2019-04-24

Related Papers

Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis.

2019-09-0340 citations

Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis.

2018-01-177 citations

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

2015-01-0994 citations

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

2015-01-0846 citations

Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.

2010-06-1754 citations

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.

2009-09-0178 citations